Diminished Ovarian Reserve

Women's Health
2
Pipeline Programs
2
Companies
2
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

M&
GANIRELIX ACETATEApproved
ganirelix acetate
Merck & Co.
injection1999

Competitive Landscape

2 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
1 program
1
Ganirelix acetatePhase 41 trial
Active Trials
NCT01614067Terminated30Est. Sep 2014
Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
1 program
whole-genome sequencingN/A1 trial
Active Trials
NCT04711772Unknown140Est. Dec 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Merck & Co.Ganirelix acetate
Ferring Pharmaceuticalswhole-genome sequencing

Clinical Trials (2)

Total enrollment: 170 patients across 2 trials

NCT01614067Merck & Co.Ganirelix acetate

Delayed Start to Ovarian Stimulation

Start: May 2012Est. completion: Sep 201430 patients
Phase 4Terminated
NCT04711772Ferring Pharmaceuticalswhole-genome sequencing

Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve

Start: Sep 2020Est. completion: Dec 2022140 patients
N/AUnknown

Related Jobs in Women's Health

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space